LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article ; Online: DNA of mouse mammary tumor virus-like virus is present in human tumors influenced by hormones.

Johal, Harpreet / Faedo, Margaret / Faltas, Jacqueline / Lau, Amie / Mousina, Railya / Cozzi, Paul / Defazio, Anna / Rawlinson, William D

Journal of medical virology

2010 Volume 82, Issue 6, Page(s) 1044–1050

Abstract: Mouse mammary tumor virus (MMTV) is a hormonally regulated, oncogenic virus of mice. MMTV-like virus DNA has previously been detected in human breast cancers, liver disease, and liver cancers. It is hypothesized that local hormonal effects might be of ... ...

Abstract	Mouse mammary tumor virus (MMTV) is a hormonally regulated, oncogenic virus of mice. MMTV-like virus DNA has previously been detected in human breast cancers, liver disease, and liver cancers. It is hypothesized that local hormonal effects might be of primary importance in determining MMTV-like virus detection in human tumors. MMTV-like virus envelope (env) DNA was determined using nested PCR in 89 ovarian, 147 prostate, 50 endometrial, 141 skin, and 51 lung cancers. Viral-positive sequences were compared with published MMTV-like viral sequences from human breast cancer, liver cancer and MMTV. Immunohistochemistry for estrogen receptor (ER-alpha) and progesterone receptor (PgR) was performed on a subset of tumors. MMTV-like virus env DNA was detected in ovarian cancers (14/89; 16%), prostate cancers (53/147; 36%), endometrial cancers (5/50; 10%), skin cancers (13/141; 9%) but not in lung cancers (0/51). Phylogenetic analysis of the viral-positive sequences showed no clustering of the isolates according to tissue type. A significant association was observed between the presence of hormone receptors and detection of MMTV-like virus in the human cancers screened (P = 0.01). A significant association between MMTV-like virus and PgR was noted in skin cancers (P = 0.003). Therefore, unlike the mouse model, the detection of MMTV-like env sequences in human cancers in addition to breast indicates that MMTV-like viral expression is not breast cancer-specific and may relate to hormone-dependent viral expression.
MeSH term(s)	DNA, Viral/chemistry ; DNA, Viral/genetics ; Endometrial Neoplasms/pathology ; Endometrial Neoplasms/virology ; Estrogen Receptor alpha/analysis ; Female ; Hormones/pharmacology ; Humans ; Immunohistochemistry ; Lung Neoplasms/pathology ; Lung Neoplasms/virology ; Male ; Mammary Tumor Virus, Mouse/genetics ; Molecular Sequence Data ; Neoplasms/virology ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/virology ; Polymerase Chain Reaction ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/virology ; Receptors, Progesterone/analysis ; Retroviridae/genetics ; Retroviridae/isolation & purification ; Skin Neoplasms/pathology ; Skin Neoplasms/virology ; Viral Envelope Proteins/genetics
Chemical Substances	DNA, Viral ; Estrogen Receptor alpha ; Hormones ; Receptors, Progesterone ; Viral Envelope Proteins
Language	English
Publishing date	2010-05
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.21754
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.

Guminski, Alexander D / Balleine, Rosemary L / Chiew, Yoke-Eng / Webster, Lucy R / Tapner, Michael / Farrell, Geoffrey C / Harnett, Paul R / Defazio, Anna

Gynecologic oncology

2006 Volume 100, Issue 2, Page(s) 239–246

Abstract: Objective: The ABC transporter MRP2 (ABCC2) can mediate cisplatin efflux, and over-expression of MRP2 has been associated with cisplatin resistance in cancer cell lines. The aim of this study was to determine the role of MRP2 in modulating cisplatin ... ...

Abstract	Objective: The ABC transporter MRP2 (ABCC2) can mediate cisplatin efflux, and over-expression of MRP2 has been associated with cisplatin resistance in cancer cell lines. The aim of this study was to determine the role of MRP2 in modulating cisplatin cytotoxicity in normal cells as well as the relationship between MRP2 expression and clinical response to platinum-based agents in ovarian cancer. Methods: The effect of absence of MRP2 expression on cisplatin sensitivity was investigated using primary hepatocyte cultures from the TR- rat strain, which is deficient in Mrp2. We also examined MRP2 expression immunohistochemically in human ovarian tumors exhibiting extremes of clinical response to platinum-based chemotherapy, either absolute platin resistance or patients with residual disease after surgery who experienced extremely long complete response to primary platinum-based chemotherapy. Results: Primary hepatocyte cultures from Mrp2-deficient TR- rats were over threefold more sensitive to cisplatin and accumulated a twofold greater amount of platinum on DNA that wild-type rat hepatocytes. In human ovarian carcinomas, MRP2 was detected by immunohistochemistry in 3/13 (23%) tumors from patients with absolute platin resistance compared with 5/9 (56%) tumors from patients with prolonged survival following treatment including a platinum-based agent. Conclusion: These studies indicate that MRP2 may play an important role in modulating normal tissue response to cisplatin. However, MRP2 expression occurred only in a subset of primary ovarian cancers, was frequently aberrant in location and was not correlated with clinical response to platinum-based chemotherapy.
MeSH term(s)	Animals ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Cisplatin/pharmacokinetics ; Cisplatin/pharmacology ; Dose-Response Relationship, Drug ; Drug Resistance, Neoplasm ; Female ; Hepatocytes/drug effects ; Hepatocytes/metabolism ; Humans ; Immunohistochemistry ; Liver/drug effects ; Liver/metabolism ; Male ; Membrane Transport Proteins/biosynthesis ; Membrane Transport Proteins/deficiency ; Membrane Transport Proteins/metabolism ; Middle Aged ; Multidrug Resistance-Associated Proteins/biosynthesis ; Multidrug Resistance-Associated Proteins/deficiency ; Multidrug Resistance-Associated Proteins/metabolism ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/metabolism ; Rats ; Rats, Wistar
Chemical Substances	Antineoplastic Agents ; Membrane Transport Proteins ; Multidrug Resistance-Associated Proteins ; multidrug resistance-associated protein 2 (4AF605U6JN) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2006-02
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	801461-9
ISSN	1095-6859 ; 0090-8258
ISSN (online)	1095-6859
ISSN	0090-8258
DOI	10.1016/j.ygyno.2005.08.046
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 885: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Byrne, Jennifer A / Maleki, Sanaz / Hardy, Jayne R / Gloss, Brian S / Murali, Rajmohan / Scurry, James P / Fanayan, Susan / Emmanuel, Catherine / Hacker, Neville F / Sutherland, Robert L / Defazio, Anna / O'Brien, Philippa M

BMC cancer

2010 Volume 10, Page(s) 497

Abstract: Background: The four-transmembrane MAL2 protein is frequently overexpressed in breast carcinoma, and MAL2 overexpression is associated with gain of the corresponding locus at chromosome 8q24.12. Independent expression microarray studies predict MAL2 ... ...

Abstract	Background: The four-transmembrane MAL2 protein is frequently overexpressed in breast carcinoma, and MAL2 overexpression is associated with gain of the corresponding locus at chromosome 8q24.12. Independent expression microarray studies predict MAL2 overexpression in ovarian carcinoma, but these had remained unconfirmed. MAL2 binds tumor protein D52 (TPD52), which is frequently overexpressed in ovarian carcinoma, but the clinical significance of MAL2 and TPD52 overexpression was unknown. Methods: Immunohistochemical analyses of MAL2 and TPD52 expression were performed using tissue microarray sections including benign, borderline and malignant epithelial ovarian tumours. Inmmunohistochemical staining intensity and distribution was assessed both visually and digitally. Results: MAL2 and TPD52 were significantly overexpressed in high-grade serous carcinomas compared with serous borderline tumours. MAL2 expression was highest in serous carcinomas relative to other histological subtypes, whereas TPD52 expression was highest in clear cell carcinomas. MAL2 expression was not related to patient survival, however high-level TPD52 staining was significantly associated with improved overall survival in patients with stage III serous ovarian carcinoma (log-rank test, p < 0.001; n = 124) and was an independent predictor of survival in the overall carcinoma cohort (hazard ratio (HR), 0.498; 95% confidence interval (CI), 0.34-0.728; p < 0.001; n = 221), and in serous carcinomas (HR, 0.440; 95% CI, 0.294-0.658; p < 0.001; n = 182). Conclusions: MAL2 is frequently overexpressed in ovarian carcinoma, and TPD52 overexpression is a favourable independent prognostic marker of potential value in the management of ovarian carcinoma patients.
MeSH term(s)	Adenocarcinoma, Clear Cell/metabolism ; Adenocarcinoma, Clear Cell/pathology ; Adenocarcinoma, Mucinous/metabolism ; Adenocarcinoma, Mucinous/pathology ; Biomarkers, Tumor/metabolism ; Cohort Studies ; Cystadenocarcinoma, Serous/metabolism ; Cystadenocarcinoma, Serous/pathology ; Endometrial Neoplasms/metabolism ; Endometrial Neoplasms/pathology ; Female ; Humans ; Immunoenzyme Techniques ; Middle Aged ; Myelin and Lymphocyte-Associated Proteolipid Proteins ; Neoplasm Proteins/metabolism ; Neoplasm Staging ; Neoplasm, Residual/metabolism ; Neoplasm, Residual/pathology ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Prognosis ; Proteolipids/metabolism ; Survival Rate ; Tissue Array Analysis ; Vesicular Transport Proteins/metabolism
Chemical Substances	Biomarkers, Tumor ; MAL2 protein, human ; Myelin and Lymphocyte-Associated Proteolipid Proteins ; Neoplasm Proteins ; Proteolipids ; TPD52 protein, human ; Vesicular Transport Proteins
Language	English
Publishing date	2010-09-17
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1471-2407
ISSN (online)	1471-2407
DOI	10.1186/1471-2407-10-497
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

Ahmed, Ahmed Ashour / Etemadmoghadam, Dariush / Temple, Jillian / Lynch, Andy G / Riad, Mohamed / Sharma, Raghwa / Stewart, Colin / Fereday, Sian / Caldas, Carlos / Defazio, Anna / Bowtell, David / Brenton, James D

The Journal of pathology

2010 Volume 221, Issue 1, Page(s) 49–56

Abstract: Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) ...

Abstract	Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high-grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of TP53 mutations in HGPSC, we sequenced exons 2-11 and intron-exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 and FIGO stage III or IV. Surprisingly, pathogenic TP53 mutations were identified in 96.7% (n = 119/123) of HGPSC cases. Molecular and pathological review of mutation-negative cases showed evidence of p53 dysfunction associated with copy number gain of MDM2 or MDM4, or indicated the exclusion of samples as being low-grade serous tumours or carcinoma of uncertain primary site. Overall, p53 dysfunction rate approached 100% of confirmed HGPSCs. No association between TP53 mutation and progression-free or overall survival was found. From this first comprehensive mapping of TP53 mutation rate in a homogeneous group of HGPSC patients, we conclude that mutant TP53 is a driver mutation in the pathogenesis of HGPSC cancers. Because TP53 mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance.
MeSH term(s)	Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/pathology ; DNA, Neoplasm/genetics ; Disease Progression ; Exons/genetics ; Female ; Genes, p53/genetics ; Genetic Predisposition to Disease ; Humans ; Middle Aged ; Mutation ; Neoplasm Staging ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Pilot Projects ; Prognosis ; Survival Analysis ; Treatment Outcome ; Young Adult
Chemical Substances	DNA, Neoplasm
Language	English
Publishing date	2010-03-13
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	3119-7
ISSN	1096-9896 ; 0022-3417
ISSN (online)	1096-9896
ISSN	0022-3417
DOI	10.1002/path.2696
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.12: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.

Byrne, Jennifer A / Balleine, Rosemary L / Schoenberg Fejzo, Marlena / Mercieca, Janelle / Chiew, Yoke-Eng / Livnat, Yael / St Heaps, Luke / Peters, Gregory B / Byth, Karen / Karlan, Beth Y / Slamon, Dennis J / Harnett, Paul / Defazio, Anna

International journal of cancer

2005 Volume 117, Issue 6, Page(s) 1049–1054

Abstract: Recurrent chromosome 8q gain in ovarian carcinoma is likely to reflect the existence of multiple target loci, as the separate gain of chromosome bands 8q21 and 8q24 has been reported in independent studies. Since tumor protein D52 (TPD52) has been ... ...

Abstract	Recurrent chromosome 8q gain in ovarian carcinoma is likely to reflect the existence of multiple target loci, as the separate gain of chromosome bands 8q21 and 8q24 has been reported in independent studies. Since tumor protein D52 (TPD52) has been identified as a chromosome 8q21 amplification target in breast and prostate carcinoma, we compared TPD52 expression in normal ovarian epithelium (n = 9), benign serous adenomas (n = 11), serous borderline tumors (n = 6) and invasive carcinomas of the major histologic subtypes (n = 57) using immunohistochemistry. These analyses revealed that all normal ovarian epithelium samples and benign serous tumors were predominantly TPD52-negative, whereas TPD52 was overexpressed in most (44/57; 77%) ovarian carcinomas regardless of histologic subtype. TPD52 subcellular localization was predominantly cytoplasmic, although nuclear localization was also frequently observed in mucinous and clear cell carcinomas. In an independent cohort of stage III serous carcinomas (n = 18), we also directly compared in situ TPD52 expression using immunohistochemistry and TPD52 copy number using interphase FISH analyses. This revealed that TPD52 dosage and TPD52 expression were significantly positively correlated. TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number.
MeSH term(s)	Biomarkers, Tumor/analysis ; CA-125 Antigen/blood ; Chromosomes, Human, Pair 8 ; Female ; Gene Amplification/genetics ; Gene Expression ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Middle Aged ; Neoplasm Proteins/analysis ; Neoplasm Proteins/genetics ; Ovarian Neoplasms/chemistry ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Ovary/chemistry
Chemical Substances	Biomarkers, Tumor ; CA-125 Antigen ; Neoplasm Proteins ; TPD52 protein, human
Language	English
Publishing date	2005-12-20
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	218257-9
ISSN	1097-0215 ; 0020-7136
ISSN (online)	1097-0215
ISSN	0020-7136
DOI	10.1002/ijc.21250
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 478: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 576: Show issues

Order via subito

Details ▾

Article: Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.

Johnatty, Sharon E / Beesley, Jonathan / Chen, Xiaoqing / Spurdle, Amanda B / Defazio, Anna / Webb, Penelope M / Goode, Ellen L / Rider, David N / Vierkant, Robert A / Anderson, Stephanie / Wu, Anna H / Pike, Malcolm / Van Den Berg, David / Moysich, Kirsten / Ness, Roberta / Doherty, Jennifer / Rossing, Mary-Anne / Pearce, Celeste Leigh / Chenevix-Trench, Georgia

Twin research and human genetics : the official journal of the International Society for Twin Studies

2009 Volume 12, Issue 3, Page(s) 269–275

Abstract: Fibroblast growth factor (FGF)-2 (basic) is a potent angiogenic molecule involved in tumor progression, and is one of several growth factors with a central role in ovarian carcinogenesis. We hypothesized that common single nucleotide polymorphisms (SNPs) ...

Abstract	Fibroblast growth factor (FGF)-2 (basic) is a potent angiogenic molecule involved in tumor progression, and is one of several growth factors with a central role in ovarian carcinogenesis. We hypothesized that common single nucleotide polymorphisms (SNPs) in the FGF2 gene may alter angiogenic potential and thereby susceptibility to ovarian cancer. We analyzed 25 FGF2 tgSNPs using five independent study populations from the United States and Australia. Analysis was restricted to non-Hispanic White women with serous ovarian carcinoma (1269 cases and 2829 controls). There were no statistically significant associations between any FGF2 SNPs and ovarian cancer risk. There were two nominally statistically significant associations between heterozygosity for two FGF2 SNPs (rs308379 and rs308447; p < .05) and serous ovarian cancer risk in the combined dataset, but rare homozygous estimates did not achieve statistical significance, nor were they consistent with the log additive model of inheritance. Overall genetic variation in FGF2 does not appear to play a role in susceptibility to ovarian cancer.
MeSH term(s)	Australia ; Case-Control Studies ; Female ; Fibroblast Growth Factor 2/genetics ; Humans ; Ovarian Neoplasms/epidemiology ; Ovarian Neoplasms/genetics ; Polymorphism, Genetic ; Population Groups/genetics ; Risk Factors ; Serous Membrane/pathology ; United States
Chemical Substances	Fibroblast Growth Factor 2 (103107-01-3)
Language	English
Publishing date	2009-05-20
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2182682-1
ISSN	1839-2628 ; 1832-4274
ISSN (online)	1839-2628
ISSN	1832-4274
DOI	10.1375/twin.12.3.269
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5127: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.

Huang, R Stephanie / Johnatty, Sharon E / Gamazon, Eric R / Im, Hae Kyung / Ziliak, Dana / Duan, Shiwei / Zhang, Wei / Kistner, Emily O / Chen, Peixian / Beesley, Jonathan / Mi, Shuangli / O'Donnell, Peter H / Fraiman, Yarden S / Das, Soma / Cox, Nancy J / Lu, Yi / Macgregor, Stuart / Goode, Ellen L / Vierkant, Robert A /

Fridley, Brooke L / Hogdall, Estrid / Kjaer, Susanne K / Jensen, Allan / Moysich, Kirsten B / Grasela, Matthew / Odunsi, Kunle / Brown, Robert / Paul, Jim / Lambrechts, Diether / Despierre, Evelyn / Vergote, Ignace / Gross, Jenny / Karlan, Beth Y / Defazio, Anna / Chenevix-Trench, Georgia / Dolan, M Eileen

Clinical cancer research : an official journal of the American Association for Cancer Research

2011 Volume 17, Issue 16, Page(s) 5490–5500

Abstract: Purpose: Cell-based approaches were used to identify genetic markers predictive of patients' risk for poor response prior to chemotherapy.: Experimental design: We conducted genome-wide association studies (GWAS) to identify single-nucleotide ... ...

Abstract	Purpose: Cell-based approaches were used to identify genetic markers predictive of patients' risk for poor response prior to chemotherapy. Experimental design: We conducted genome-wide association studies (GWAS) to identify single-nucleotide polymorphisms (SNP) associated with cellular sensitivity to carboplatin through their effects on mRNA expression using International HapMap lymphoblastoid cell lines (LCL) and replicated them in additional LCLs. SNPs passing both stages of the cell-based study were tested for association with progression-free survival (PFS) in patients. Phase 1 validation was based on 377 ovarian cancer patients receiving at least four cycles of carboplatin and paclitaxel from the Australian Ovarian Cancer Study (AOCS). Positive associations were then assessed in phase 2 validation analysis of 1,326 patients from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Results: In the initial GWAS, 342 SNPs were associated with carboplatin-induced cytotoxicity, of which 18 unique SNPs were retained after assessing their association with gene expression. One SNP (rs1649942) was replicated in an independent LCL set (Bonferroni adjusted P < 0.05). It was found to be significantly associated with decreased PFS in phase 1 AOCS patients (P(per-allele) = 2 × 10(-2)), with a stronger effect in the subset of women with optimally debulked tumors (P(per-allele) = 4 × 10(-3)). rs1649942 was also associated with poorer overall survival in women with optimally debulked tumors (P(per-allele) = 9 × 10(-3)). However, this SNP was not significant in phase 2 validation analysis with patients from numerous cohorts. Conclusion: This study shows the potential of cell-based, genome-wide approaches to identify germline predictors of treatment outcome and highlights the need for extensive validation in patients to assess their clinical effect.
MeSH term(s)	Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carboplatin/therapeutic use ; Cell Line ; Cell Line, Tumor ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Genome, Human/genetics ; Genome-Wide Association Study/methods ; Humans ; Kaplan-Meier Estimate ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Polymorphism, Single Nucleotide ; Prognosis ; Treatment Outcome
Chemical Substances	Antineoplastic Agents ; Carboplatin (BG3F62OND5)
Language	English
Publishing date	2011-06-24
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-11-0724
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

Verhaak, Roel G W / Tamayo, Pablo / Yang, Ji-Yeon / Hubbard, Diana / Zhang, Hailei / Creighton, Chad J / Fereday, Sian / Lawrence, Michael / Carter, Scott L / Mermel, Craig H / Kostic, Aleksandar D / Etemadmoghadam, Dariush / Saksena, Gordon / Cibulskis, Kristian / Duraisamy, Sekhar / Levanon, Keren / Sougnez, Carrie / Tsherniak, Aviad / Gomez, Sebastian /

The Journal of clinical investigation

2012 Volume 123, Issue 1, Page(s) 517–525

Abstract: Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome Atlas (TCGA), we developed subtype and ... ...

Abstract	Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome Atlas (TCGA), we developed subtype and survival gene expression signatures, which, when combined, provide a prognostic model of HGS-OvCa classification, named "Classification of Ovarian Cancer" (CLOVAR). We validated CLOVAR on an independent dataset consisting of 879 HGS-OvCa expression profiles. The worst outcome group, accounting for 23% of all cases, was associated with a median survival of 23 months and a platinum resistance rate of 63%, versus a median survival of 46 months and platinum resistance rate of 23% in other cases. Associating the outcome prediction model with BRCA1/BRCA2 mutation status, residual disease after surgery, and disease stage further optimized outcome classification. Ovarian cancer is a disease in urgent need of more effective therapies. The spectrum of outcomes observed here and their association with CLOVAR signatures suggests variations in underlying tumor biology. Prospective validation of the CLOVAR model in the context of additional prognostic variables may provide a rationale for optimal combination of patient and treatment regimens.
MeSH term(s)	Adult ; Aged ; BRCA1 Protein/biosynthesis ; BRCA1 Protein/genetics ; BRCA2 Protein/biosynthesis ; BRCA2 Protein/genetics ; Disease-Free Survival ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Middle Aged ; Models, Biological ; Mutation ; Neoplasm Grading ; Ovarian Neoplasms/classification ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/therapy ; Predictive Value of Tests ; Prospective Studies ; Survival Rate
Chemical Substances	BRCA1 Protein ; BRCA1 protein, human ; BRCA2 Protein ; BRCA2 protein, human
Language	English
Publishing date	2012-12-21
Publishing country	United States
Document type	Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	3067-3
ISSN	1558-8238 ; 0021-9738
ISSN (online)	1558-8238
ISSN	0021-9738
DOI	10.1172/JCI65833
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.184: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.

White, Kristin L / Vierkant, Robert A / Fogarty, Zachary C / Charbonneau, Bridget / Block, Matthew S / Pharoah, Paul D P / Chenevix-Trench, Georgia / Rossing, Mary Anne / Cramer, Daniel W / Pearce, Celeste Leigh / Schildkraut, Joellen M / Menon, Usha / Kjaer, Susanne Kruger / Levine, Douglas A / Gronwald, Jacek / Culver, Hoda Anton / Whittemore, Alice S / Karlan, Beth Y / Lambrechts, Diether /

Wentzensen, Nicolas / Kupryjanczyk, Jolanta / Chang-Claude, Jenny / Bandera, Elisa V / Hogdall, Estrid / Heitz, Florian / Kaye, Stanley B / Fasching, Peter A / Campbell, Ian / Goodman, Marc T / Pejovic, Tanja / Bean, Yukie / Lurie, Galina / Eccles, Diana / Hein, Alexander / Beckmann, Matthias W / Ekici, Arif B / Paul, James / Brown, Robert / Flanagan, James M / Harter, Philipp / du Bois, Andreas / Schwaab, Ira / Hogdall, Claus K / Lundvall, Lene / Olson, Sara H / Orlow, Irene / Paddock, Lisa E / Rudolph, Anja / Eilber, Ursula / Dansonka-Mieszkowska, Agnieszka / Rzepecka, Iwona K / Ziolkowska-Seta, Izabela / Brinton, Louise / Yang, Hannah / Garcia-Closas, Montserrat / Despierre, Evelyn / Lambrechts, Sandrina / Vergote, Ignace / Walsh, Christine / Lester, Jenny / Sieh, Weiva / McGuire, Valerie / Rothstein, Joseph H / Ziogas, Argyrios / Lubinski, Jan / Cybulski, Cezary / Menkiszak, Janusz / Jensen, Allan / Gayther, Simon A / Ramus, Susan J / Gentry-Maharaj, Aleksandra / Berchuck, Andrew / Wu, Anna H / Pike, Malcolm C / Van Denberg, David / Terry, Kathryn L / Vitonis, Allison F / Doherty, Jennifer A / Johnatty, Sharon E / Defazio, Anna / Song, Honglin / Tyrer, Jonathan / Sellers, Thomas A / Phelan, Catherine M / Kalli, Kimberly R / Cunningham, Julie M / Fridley, Brooke L / Goode, Ellen L

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

2013 Volume 22, Issue 5, Page(s) 987–992

Abstract: Background: Ovarian cancer is a leading cause of cancer-related death among women. In an effort to understand contributors to disease outcome, we evaluated single-nucleotide polymorphisms (SNP) previously associated with ovarian cancer recurrence or ... ...

Abstract	Background: Ovarian cancer is a leading cause of cancer-related death among women. In an effort to understand contributors to disease outcome, we evaluated single-nucleotide polymorphisms (SNP) previously associated with ovarian cancer recurrence or survival, specifically in angiogenesis, inflammation, mitosis, and drug disposition genes. Methods: Twenty-seven SNPs in VHL, HGF, IL18, PRKACB, ABCB1, CYP2C8, ERCC2, and ERCC1 previously associated with ovarian cancer outcome were genotyped in 10,084 invasive cases from 28 studies from the Ovarian Cancer Association Consortium with over 37,000-observed person-years and 4,478 deaths. Cox proportional hazards models were used to examine the association between candidate SNPs and ovarian cancer recurrence or survival with and without adjustment for key covariates. Results: We observed no association between genotype and ovarian cancer recurrence or survival for any of the SNPs examined. Conclusions: These results refute prior associations between these SNPs and ovarian cancer outcome and underscore the importance of maximally powered genetic association studies. Impact: These variants should not be used in prognostic models. Alternate approaches to uncovering inherited prognostic factors, if they exist, are needed.
MeSH term(s)	Female ; Genetic Association Studies ; Genetic Predisposition to Disease ; Genotype ; Humans ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/mortality ; Polymorphism, Genetic ; Polymorphism, Single Nucleotide ; Prognosis ; Proportional Hazards Models ; Survival Analysis
Language	English
Publishing date	2013-03-19
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	1153420-5
ISSN	1538-7755 ; 1055-9965
ISSN (online)	1538-7755
ISSN	1055-9965
DOI	10.1158/1055-9965.EPI-13-0028
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3693: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito